| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8215435 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 30 Pages |
Abstract
Gemcitabine concurrent with RT is well-tolerated and yields promising outcomes, including in patients with adverse molecular features. It is a candidate for further study, particularly for poor-prognosis patient subgroups with HGG.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michelle M. MD, Sandra MD, Matthew PhD, Yebin MS, Daniel PhD, Larry MD, Aaron MD, Bryan L. PhD, Yue PhD, Christopher J. BA, Jason MD, Oren MD, Theodore S. MD, PhD, Christina I. MD,